About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Enter your email address:

Delivered by FeedBurner

Contact the Docs

Docs on Twitter


Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« Cancer Drug Development in The New York Times | Main | ACI Pharma/Biotech Collaborative Agreements Conference »

September 03, 2009

Comments

Re: "free-riders"

Except, of course, where US companies are denied patent protection for biotech inventions that are then freely made and sold in Europe.

Any data in his report about which of the NCEs (US vs. EU vs. JP) were the most profitable? Wouldn't it also be consistent with his data if the lower amount of investment in Europe resulted in fewer blockbuster drugs? And did he compare the requirements for safety and efficacy in the EU vs. the US (since a large part of the cost of bringing drugs to market in the US are due to regulatory requirements)?

I am generally skeptical when data from one study is repackaged by another researcher, especially when the conclusions so clearly favor the researcher's sponsor.

But you read the report - any insights?

"Congressional leaders and others concerned about high prices of new patented drugs will be heartened by this analysis, because lower European prices seem to be no deterrent to strong research productivity."

This really is an asinine statement. When the U.S. comprises at least 50-75% of the world-wide market, of course that lower prices in 10-30% of the world-wide market would not be a deterrent to strong research productivity. Can he really make this statement with a straight face if the U.S. were to significantly lower prices? Especially in light of the fact that development costs had not decreased over the last decade but in fact significantly increased.

The comments to this entry are closed.

August 2020

Sun Mon Tue Wed Thu Fri Sat
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31